Review article: the clinical role of anti‐TNFα antibody treatment in Crohn's disease
Authors:
- 1 May 2000
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (5) , 501-514
Abstract
The recent licensing of anti‐TNFα antibody treatment offers the potential to radically alter the course of severe Crohn's disease using genetically‐engineered drugs directed against a specific inflammatory mediator. Controlled randomized trials have demonstrated clinical benefit associated with tissue healing in patients with active intestinal disease and fistulae, often when conventional therapies were unsuccessful. This therapy is expensive, however, and long‐term efficacy and safety data are still awaited. This review considers the nature of this therapy and the current evidence for its clinical benefit and adverse effects. The treatment is also considered in the context of available immunosuppressive agents, with suggestions about its practical application.Keywords
This publication has 70 references indexed in Scilit:
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisGastroenterology, 1999
- Diagnoses of extraintestinal manifestations and cancers in IBD in large population-based databasesGastroenterology, 1998
- Dose raising of azathioprine beyond 2.5 MG/KG/day in Crohn's disease patients who fail to improve with a standard doseGastroenterology, 1998
- Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential usesJournal of the American Academy of Dermatology, 1996
- Efficacy of cyclosporine in treatment of fistula of crohn's diseaseDigestive Diseases and Sciences, 1994
- Construction and initial characterization of a mouse-human chimeric anti-TNF antibodyMolecular Immunology, 1993
- Final Report on a Placebo-Controlled, Double-Blind, Randomized, Multicentre Trial of Cyclosporin Treatment in Active Chronic Crohn's DiseaseScandinavian Journal of Gastroenterology, 1991
- Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.Journal of Experimental Medicine, 1990
- Treatment of Crohn's Disease with 6-MercaptopurineNew England Journal of Medicine, 1980